@Article{Rokicka-Piotrowicz2001,
journal="Contemporary Oncology/Współczesna Onkologia",
issn="1428-2526",
volume="5",
number="4",
year="2001",
title="Thalidomide in the treatment of multiple myeloma",
abstract="More than three decades after its withdrawal from the world market thalidomide is attracting growing interest because of its reported antiangiogenetic, immunomodulatory and anti-inflammatory properties. Recently, the drug was approved for sale in the United States for the treatment of erythrema nodosum leprosum. This review presents a new possibility of treatment of multiple myeloma patients with thalidomide. The dosage and side effects of thalidomide are described.",
author="Rokicka-Piotrowicz, Małgorzata",
pages="161--164",
url="https://www.termedia.pl/Thalidomide-in-the-treatment-of-multiple-myeloma,3,623,1,1.html"
}